Uncovering drug-associated risk signals for neovascular age-related macular degeneration: an integrative pharmacovigilance and proteogenomic study.

Eye (London, England)

Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison.

Diabetes, obesity & metabolism

Semaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes.

Diabetes, obesity & metabolism

Combining GLP-1 Receptor Agonists and Health-Behaviour and Lifestyle Therapy Yields Higher Adherence and Reduces Session Needs for Successful Weight Management in Adolescence: An Observational Real-World Single-Center Study.

Pediatric obesity

Peptide Therapies in Thyroid Health: Emerging Applications in Endocrine and Immune Modulation.

Integrative medicine (Encinitas, Calif.)

Incretin-Based Therapy and Thyroid Cancer Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

AACE endocrinology and diabetes

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Thyroid Function Tests: A Systematic Review Identifying a Critical Evidence Gap.

Cureus

A Review of the Oral Semaglutide in Adults with Overweight or Obesity (OASIS) Trials Evaluating Oral Semaglutide (Wegovy) for Chronic Weight Management in Adults With Overweight or Obesity.

Cureus

📢 ผลเสียของการปักกาที่ไม่มีใครเตือน‼️ ⛔ระวังสูญเสียมวลกล้ามเนื้อและกระดูกพรุน ​ยากลุ่ม GLP-1 receptor agonists คือยาจำพวก เซมากลูไทด์ (Semaglutide - ชื่อการค้า Ozempic, Wegovy) และยาทิรเซพาไทด์ (Tirzepatide - ชื่อการค้า Mounjaro, Zepbound) จากการวิจัยภายใน 52 อาทิตย์ https://t.co/MoXEVORcgI

RT @afshineemrani: 2/5 The study matched patients on GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide, and others — against…

RT @afshineemrani: 2/5 The study matched patients on GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide, and others — against…

RT @afshineemrani: 2/5 The study matched patients on GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide, and others — against…

@nicknorwitz Imagine knee or shoulder surgery along with IV drip of BPC-157 pre, during, and post surgery recovery. 24hrs of peptide therapy. Hospital and fda approved. Maybe hgh and IGF as well.

RT @gemoscatelli: Fastest growing business/sales in 2026: weight loss, obesity, diabetes, GIP/GLP-1 agonists (tirzepatide and semaglutide)…

🧠 Could tirzepatide protect the brain better than semaglutide? Real-world cohort in T2D: #tirzepatide → dramatically lower rates of dementia and Alzheimer’s vs. semaglutide. Dual GIP/GLP-1 agonism may offer superior neuroprotection. Exciting — but needs prospective https://t.co/L8xXc7JuwM

@ThePepGuy verve 102 results are interesting peptide therapy also shows promise for lipid profiles bpc 157 and tb 500 have been studied for their effects on inflammation and cardiovascular health worth looking into the molecular mechanisms behind them.